Hepion Pharmaceuticals, Inc. (HEPA)
- Previous Close
1.2900 - Open
1.2700 - Bid --
- Ask --
- Day's Range
1.2700 - 1.4300 - 52 Week Range
1.2200 - 20.6600 - Volume
39,592 - Avg. Volume
77,916 - Market Cap (intraday)
7.497M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-12.3200 - Earnings Date May 13, 2024 - May 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.00
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
www.hepionpharma.comRecent News: HEPA
Performance Overview: HEPA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HEPA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HEPA
Valuation Measures
Market Cap
7.06M
Enterprise Value
-5.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.26
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.12
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-72.21%
Return on Equity (ttm)
-171.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-48.93M
Diluted EPS (ttm)
-12.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
14.79M
Total Debt/Equity (mrq)
2.87%
Levered Free Cash Flow (ttm)
-25.88M
Research Analysis: HEPA
Company Insights: HEPA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: HEPA
Daily – Vickers Top Insider Picks for 03/01/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/24/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/23/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/22/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.